Indirubin derivative acts as dual inhibitor targeting proteasome and autophagy for treating multiple myeloma

被引：0
|
作者：
Fang, Teng [1 ]
Sun, Hao [1 ]
Sun, Xiyue [2 ]
Zhang, Xiaoyu [2 ]
Gong, Lixin [1 ]
Yu, Zhen [1 ]
Liu, Lanting [1 ]
Qiu, Lugui [1 ]
Hao, Mu [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol,Haihe Lab Cell Ecosyst, Tianjin 300020, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-189
引用
收藏
页码：S139 / S140
页数：2
相关论文
共 50 条
  • [21] The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma
    Richardson, Paul G.
    Moreau, Philippe
    Laubach, Jacob P.
    Gupta, Neeraj
    Hui, Ai-Min
    Anderson, Kenneth C.
    Miguel, Jesus F. San
    Kumar, Shaji
    FUTURE ONCOLOGY, 2015, 11 (08) : 1153 - 1168
  • [22] CRIP1 Involves the Pathogenesis of Multiple Myeloma Via Dual-Regulation of Proteasome and Autophagy
    Yu, Zhen
    Tang, Peixia
    Xu, Zhenshu
    Qiu, Lugui
    Hao, Mu
    BLOOD, 2023, 142
  • [23] CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy
    Tang, Peixia
    Yu, Zhen
    Sun, Hao
    Liu, Lanting
    Gong, Lixin
    Fang, Teng
    Sun, Xiyue
    Xie, Shiyi
    An, Gang
    Xu, Zhenshu
    Qiu, Lugui
    Hao, Mu
    EBIOMEDICINE, 2024, 100
  • [24] The role of cystatin C as a proteasome inhibitor in multiple myeloma
    Jiang, Yijing
    Zhang, Jie
    Zhang, Chenlu
    Hong, Lemin
    Jiang, Yuwen
    Lu, Ling
    Huang, Hongming
    Guo, Dan
    HEMATOLOGY, 2020, 25 (01) : 457 - 463
  • [25] Bortezomib - first proteasome inhibitor for the treatment of multiple Myeloma
    Jurczyszyn, Artur
    Skotnicki, Aleksander B.
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2007, 11 (03): : 112 - 124
  • [26] A Novel Indirubin-3-Monoxime Derivative Functions As Regulator of Proteostasis Via Targeting TRIM28 in Multiple Myeloma
    Fang, Teng
    Sun, Hao
    Sun, Xiyue
    Yu, Zhen
    Zhang, Xiaoyu
    Liu, Lanting
    Gong, Lixin
    Xie, Shiyi
    Hao, Mu
    Qiu, Lugui
    BLOOD, 2023, 142
  • [27] The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors
    Toscani, Denise
    Palumbo, Carla
    Dalla Palma, Benedetta
    Ferretti, Marzia
    Bolzoni, Marina
    Marchica, Valentina
    Sena, Paola
    Martella, Eugenia
    Mancini, Cristina
    Ferri, Valentina
    Costa, Federica
    Accardi, Fabrizio
    Craviotto, Luisa
    Aversa, Franco
    Giuliani, Nicola
    JOURNAL OF BONE AND MINERAL RESEARCH, 2016, 31 (04) : 815 - 827
  • [28] A Novel Dual HDAC6 and Proteasome Inhibitor Elicits Outstanding Cytotoxicity Against Multiple Myeloma
    Teng, Fang
    Liu, Lanting
    Sun, Hao
    Zhang, Xiaoyu
    Sun, Xiyue
    Yu, Zhen
    Qiu, Lugui
    Hao, Mu
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S190 - S190
  • [29] SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma
    Heynen, Guus J. J. E.
    Baumgartner, Francis
    Heider, Michael
    Patra, Upayan
    Holz, Maximilian
    Braune, Jan
    Kaiser, Melanie
    Schaeffer, Isabell
    Bamopoulos, Stefanos A.
    Ramberger, Evelyn
    Murgai, Arunima
    Ng, Yuen Lam Dora
    Demel, Uta Margareta
    Laue, Dominik
    Liebig, Sven
    Krueger, Josefine
    Janz, Martin
    Nogai, Axel
    Schick, Markus
    Mertins, Philipp
    Mueller, Stefan
    Bassermann, Florian
    Kroenke, Jan
    Keller, Ulrich
    Wirth, Matthias
    BLOOD ADVANCES, 2023, 7 (04) : 469 - 481
  • [30] Next-generation proteasome inhibitor approved in multiple myeloma
    Alla Katsnelson
    Nature Biotechnology, 2012, 30 : 1011 - 1012
12345